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Abstract  44 
Chemical Exchange Saturation Transfer (CEST) approach is a novel tool within magnetic resonance 45 
imaging (MRI) that allows visualization of molecules possessing exchangeable protons with water. 46 
Many molecules, employed as excipients for the formulation of finished drug products, are 47 
endowed with hydroxyl, amine or amide protons, thus can be exploitable as MRI-CEST contrast 48 
agents. Their high safety profiles allow them to be injected at very high doses. Here we investigated 49 
the MRI-CEST properties of several excipients (ascorbic acid, sucrose, N-acetyl-D-glucosamine, 50 
meglumine and 2-pyrrolidone) and tested them as tumor-detecting agents in two different murine 51 
tumor models (breast and melanoma cancers). All the investigated molecules showed remarkable 52 
CEST contrast upon i.v. administration in the range 1-3 ppm according to the type of mobile proton 53 
groups. A marked increase of CEST contrast was observed in tumor regions up to 30 min post 54 
injection. The combination of marked tumor contrast enhancement and lack of toxicity make these 55 
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 61 
Chemical Compounds studied in this article 62 
Ascorbic acid (PubChem CID: 54670067); 63 
Meglumine (PubChem CID: 8567); 64 
Sucrose (PubChem CID: 5988); 65 
N-acetyl-D-glucosamine (PubChem CID: 439174); 66 
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2-Pyrrolidone (PubChem CID: 12025); 67 
 68 
Abbreviations 69 
MRI: Magnetic Resonance Imaging 70 
CEST: Chemical Exchange Saturation Transfer 71 
i.v.: intravenous 72 
 73 
1. Introduction 74 
Medicines could not be made without the use of pharmaceutical excipients that contribute notably 75 
to guarantee efficacy and safety of the final pharmaceutical product (Casas et al., 2015). Moreover, 76 
excipients perform multiple functions, besides completing the formulation volume, such as 77 
improving bioavailability, administration and acceptance of the treatment by the patient (Loftsson, 78 
2015; Narayan, 2011; Wening and Breitkreutz, 2011). Another fundamental characteristic of 79 
excipients is their pharmacological and toxicological inactivity that allows them to be used at high 80 
doses (Abrantes et al., 2016). Several natural products, simple substances and mixtures are 81 
commonly used in formulating medicines, with chemical structures that vary from small molecules 82 
to polymers.  83 
Interestingly, most, if not all of these molecules, possess exchangeable protons (hydroxyl, amine, 84 
amide groups) that can be potentially detected by chemical exchange saturation transfer (CEST) 85 
magnetic resonance imaging (MRI) (van Zijl and Yadav, 2011; Vinogradov et al., 2013). This 86 
technique enables the indirect visualization of molecules via magnetization transfer between 87 
exchangeable protons and bulk water protons. By applying a selective radiofrequency irradiation to 88 
the mobile protons, the induced saturation is transferred to the bulk water protons, thus inducing a 89 
reduction of the water signal (Liu et al., 2013). Several natural molecules and polymers (glucose, 90 
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glycogen, glycosaminoglycan, sialic acid, gelatin) have already been exploited as MRI-CEST 91 
contrast agents, since these molecules have precedence of use with human exposure (Chan et al., 92 
2012; Jin et al., 2017; Liang et al., 2015; Ling et al., 2008; Shinar et al., 2014; van Zijl et al., 2007; 93 
Walker-Samuel et al., 2013). Also metabolites, drugs and polypeptides/proteins have been 94 
investigated to demonstrate their capability to generate contrast within this approach (Bar-Shir et 95 
al., 2015; Bar-Shir et al., 2014; Cai et al., 2015; Haris et al., 2012; Li et al., 2016; Liu et al., 2016; 96 
Longo et al., 2014a; McMahon et al., 2008; Zaiss et al., 2013). Moreover, several diamagnetic 97 
CEST agents have been proposed as exogenous probes for tumor imaging (Geraldes and Laurent, 98 
2009). However, diamagnetic molecules require high doses to discriminate their contrast from 99 
direct water saturation and from endogenous magnetization transfer effects, due to the small 100 
chemical shift difference from water.  101 
These considerations limit the effective use of exogenous molecules as CEST agents to those 102 
possessing low in vivo toxicity. According to these considerations, researchers firstly turned their 103 
attention to already clinically approved contrast agents, such as iodinated contrast media, exploiting 104 
their high safety profile and FDA approval (Aime et al., 2005b; Longo et al., 2011). Consequently, 105 
radiographic agents have been exploited for assessing tumor microenvironment properties, 106 
including perfusion (Anemone et al., 2017; Longo et al., 2016b), acidosis (Chen et al., 2015; Jones 107 
et al., 2015; Longo et al., 2016a; Longo et al., 2014b; Sun et al., 2014) and for assessing renal 108 
functionality (Longo et al., 2013; Longo et al., 2017). 109 
Pharmaceutical excipients have attracted our interest since them can be used at very high dose due 110 
to their well-known safety profiles. In addition, excipients do not have any pharmacological effects, 111 
in contrast to active pharmaceutical ingredients. Ideally, a MRI-CEST contrast agent should possess 112 
good solubility and high safety profile, it should accumulate enough in the region of interest to 113 
produce contrast; afterwards, it should be excreted through the kidneys without long-term 114 
accumulation (Aime et al., 2005a; Sherry et al., 2009). The present investigation reports the MRI-115 
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CEST properties of several pharmaceutical excipients (sucrose, N-acetyl-D-glucosamine, ascorbic 116 
acid, meglumine and 2-pyrrolidone), as novel, biocompatible MRI contrast agents for molecular 117 
imaging of tumors. We describe the in vitro MRI-CEST contrast enhancing properties and the in 118 
vivo investigation of these molecules in two murine tumor models. 119 
 120 
2. Methods 121 
2.1 Materials 122 
All chemicals (Sucrose, N-acetyl-D-glucosamine, Meglumine, 2-pyrrolidone, Ascorbic acid) were 123 
purchased from Sigma-Aldrich (Sigma Aldrich, Milan, Italy).  124 
 125 
2.2 In vitro MRI CEST acquisition 126 
Phantoms containing vials of phosphate buffer solution of Sucrose, N-acetyl-D-glucosamine, 127 
Meglumine, 2-pyrrolidone or ascorbic acid were prepared at a concentration of 30mM and titrated 128 
over a range 6-7.4 pH units. CEST-MRI experiments were performed on a vertical 7 T MRI scanner 129 
Bruker Avance 300 (Bruker, Ettlingen, Germany) using a fast spin-echo sequence with centric 130 
encoding after presaturation pulses varying in power (1.5, 2.0, 3.0 and 6.0 μT) for 5 or 7s at 37°C.  131 
A modified RARE sequence including a magnetization transfer module was used to acquire CEST-132 
weighted images from -10 to +10 ppm with increments of 0.1 ppm around the water resonance.  133 
 134 
2.3 Cell lines for xenograft tumor models 135 
TS/A cells, derived from a metastasizing mouse cell line, originated from a mammary 136 
adenocarcinoma which arose spontaneously in a BALB/c female, were grown in RPMI 1640 137 
medium supplemented with 10% fetal bovine serum (FBS), 100U/mL Penicillin with 100 µg/mL 138 
Streptomycin (Pen/Strep) and 2mM L-Glutamine (Nanni et al., 1983). B16-F10 cells, an  139 
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established murine melanoma cell line, were cultured in DMEM supplemented with 10% FBS, 100 140 
µg/ml penicillin and 100 µg /ml streptomycin. B16-F10 cells were obtained from American Type 141 
Culture Collection (ATCC). 142 
 143 
2.4 Animal experiments 144 
6-old-week female BALB/c mice (n=5 for each molecule) were inoculated subcutaneously with 2.5 145 
× 105 TS/A cells in 100 µL of PBS on both flanks and 6-old-week male C57BL/6 mice (n=5 for 146 
each molecule) were inoculated subcutaneously with 3×105 B16-f10 cell in 100 µL of PBS on both 147 
flanks. BALB/c and C57BL/6 mice (Charles River Laboratories Italia S.r.l., Calco Italia) were 148 
maintained under specific pathogen free conditions in the animal facility of the Molecular 149 
Biotechnology Center, University of Turin, and treated in accordance with the EU guidelines 150 
(EU2010/63). All in vivo studies were conducted according to approved procedures of the 151 
Institutional Animal Care and Use Committee of the University of Torino.  152 
Before imaging, mice were anaesthetized with a mixture of tiletamine/zolazepam (Zoletil 100; 153 
Vibac, Milan, Italy) 20mg/kg and xylazine (Rompun; Bayer, Milan, Italy) 5mg/kg and during the 154 
acquisition their breath rate was monitored throughout in vivo MRI experiments using a respiratory 155 
probe. Cannulation of the lateral tail vein with a catheter was exploited for intravenous injection of 156 
the investigated molecules. 157 
 158 
2.5 In vivo MRI CEST acquisition and analysis  159 
A Bruker 7T Avance 300 MRI scanner (Bruker Biospin, Ettlingen, Germany) equipped with a 30 160 
mm 1H quadrature coil was used to scan mammary adenocarcinoma (TS/A cell line) and melanoma 161 
(B16-f10 cell line) tumor bearing mice 15 days post-inoculation. After the scout image acquisition, 162 
T2w anatomical images were acquired with a Fast Spin Echo sequence and the same geometry was 163 
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used for the following CEST experiments. CEST images were acquired with a single shot FSE 164 
sequence with centric encoding (TR: 6000 ms, TE: 4.0 ms) after a CW-RF presaturation pulse of B1 165 
= 1.5 μT x 5s from a single axial slice with high in-plane resolution of 234 µm (FOV 3 cm, MTX 166 
96, zero filled to 128, slice thickness 1.5mm) with 55 frequency offsets unevenly spaced in the 167 
range ±10 ppm. Each investigated molecule was administrated intravenously at the dose of 1.2 g/kg 168 
b.w. with a single bolus of 100 μL followed by continuous infusion at a rate of 500 μL/h and CEST 169 
images were acquired before and every 10 minutes up to 30 minutes. 170 
CEST images were analyzed using homemade scripts implemented in MATLAB (The Mathworks, 171 
Inc, Natick, MA). The Z-spectra were interpolated, on a voxel-by-voxel basis, by smoothing 172 
splines, B0-shift corrected and saturation transfer efficiency (ST%) was measured by punctual 173 
analysis at 1.2 ppm (Terreno et al., 2009). For in vivo images, difference contrast maps (ΔST%) 174 
were calculated by subtracting the ST contrast after each molecules injection from the ST contrast 175 
before the injection on a per voxel basis. Extravasation fraction of each molecule was calculated as 176 
the percentage of pixels showing a ΔST% above the threshold (2%) in the manually-defined tumor 177 
region of interest. 178 
 179 
2.6 Statistical analysis  180 
Calculations were performed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA) 181 
software package; data are presented as mean ± SD unless otherwise stated. Statistical significance 182 
was established at P < 0.05. 183 
 184 
3. Results 185 
3.1 In vitro characterization of CEST properties 186 
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The investigated molecules differ for the types of mobile protons, i.e. belonging to the hydroxyl, 187 
amide and amine groups, and for the number of exchanging protons (Figure 1). The ability to yield 188 
CEST contrast in the MR images is shown in Figure 2, where the contrast efficiency (ST effect) is 189 
plotted as a function of the chemical shift. Sucrose, ascorbic acid, meglumine and N-acetyl-D-190 
glucosamine show CEST contrast peaking at ca. 0.7-1.2 ppm, due to the presence of hydroxyl 191 
protons. 2-Pyrrolidone showed a small CEST contrast at 0.7 ppm downfield from water, due to the 192 
presence of a cyclic amide (lactam) group. Both meglumine and N-acetyl-D-glucosamine showed, 193 
in addition to the less shifted hydroxyl protons, a second broad CEST contrast peak between 2 and 194 
3.5 ppm, due to amine and amide protons, respectively. As shown in Figure 2, when keeping 195 
constant the saturation field strength (1.5 µT x 7s), the CEST contrast showed a significant 196 
dependence with pH. The hydroxyl mobile protons of sucrose showed higher CEST contrast values 197 
at lower pH values (Figure 3A). Conversely, the hydroxyl protons of N-acetyl-D-glucosamine, 198 
meglumine and ascorbic acid showed a steady increase of the CEST contrast at high pH values, at 199 
all the investigated saturation field strengths (1.5 – 6 µT, Figures 3B, D and E). The CEST contrast 200 
of 2-pyrrolidone was almost independent from pH (Figure 3C). Sucrose, meglumine, ascorbic acid 201 
and N-acetyl-D-glucosamine showed in vitro a ST efficiency close to 1% per 1 mM concentration 202 
(irradiation pulse of 1.5 µT x 5s, pH 7, T=37°C; Figure 3F). The highest CEST contrast efficiency 203 
observed for sucrose (1.5 % ST per 1 mM concentration) likely depends on the large number of 204 
mobile protons (8 –OH protons), whereas 2-pyrrolidone, having only one exchanging proton, 205 
showed the lowest CEST contrast. 206 
 207 
3.2 In vivo CEST detection in tumor murine models 208 
Two cancer xenograft models, TS/A (highly metastatic mouse breast cancer cells) and B16 (mouse 209 
melanoma cancer cells) were used for in vivo experiments. CEST agents were administered at the 210 
same dose by intravenous injection through the tail vein. A pronounced increase in the CEST 211 
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contrast in both TS/A and B16 tumor models for all the investigated molecules, with an average 212 
ΔST increase in the range 2- 6% in comparison to the pre-contrast ST values was observed (Figure 213 
4). Sucrose showed a slightly higher CEST contrast in the B16 model (ΔST=4.1 ±0.7%) in respect 214 
to TS/A tumors (ΔST=2.7 ±0.5%) at all the investigated time points (Figure 4A). N-Acetyl-D-215 
glucosamine slightly raised the CEST effect from the baseline with no difference between the two 216 
tumor models (ΔST=2.1 ±0.5% and 2.5 ±0.5% for B16 and TS/A, respectively, Figure 4B). The 217 
CEST signal of meglumine increased by 4.1 ±1.0% for the B16 tumors and by 2.5 ±0.4% for the 218 
TS/A tumors (Figure 4C), at 10 min post injection (P<0.05). Ascorbic acid showed the highest 219 
enhancement in TS/A tumors (ΔST=5.4 ±1.1%) in comparison to the B16 model (ΔST=2.7 ±0.7%), 220 
with statistically significant difference already 10 min after the i.v. administration (P<0.05, Figure 221 
4D). For all the investigated molecules the CEST contrast measured in tumors persisted up to 30 222 
min after the administration. Representative CEST contrast maps overimposed on anatomical 223 
images show the differential enhancement pattern among the investigated excipients within the 224 
investigated two murine tumor models (Figure 5). In particular, ΔST images showed a marked 225 
increase in CEST contrast in B16 and TS/A tumors for meglumine and ascorbic acid, respectively. 226 
The percentage of the tumor pixels where the CEST effect was detectable (ΔST higher than 2%) is 227 
dependent on both the molecules and the tumor model (Figure 6). In particular, CEST contrast 228 
increase was higher for the B16 model than for the TS/A one. Sucrose was detected in 40-60% of 229 
the tumor area according to the tumor model, whereas all the other molecules showed a detection 230 
fraction lower than 50% of the whole tumor volume. 231 
 232 
4. Discussion 233 
This study demonstrated that several excipients can be exploited as MRI-CEST contrast agents for 234 
tumor detection in mice. A moderate to marked increase in CEST contrast in the tumor region was 235 
detected up to 30 min following intravenous administration, according to the exploited agents or the 236 
11 
 
investigated tumor models. Meglumine and ascorbic acid yielded the highest contrast enhancement 237 
(ΔST>5%) in B16 and TS/A models, respectively (Figure 4). Conversely, lower CEST 238 
enhancements were measured for sucrose and N-acetyl-D-glucosamine. The potential of glucose 239 
and its derivatives to act as MRI-CEST agents for tumor imaging has already been demonstrated 240 
(Chan et al., 2012; Walker-Samuel et al., 2013; Xu et al., 2015). However, for glucose, the main 241 
drawback was associated to its rapid metabolism once entered in the tumor cells, with consequent 242 
reduction of CEST contrast capabilities. For this reason, glucose analogs, such as 2-deoxy-glucose 243 
(2DG) and 3-oxy-methyl-gluose (3OMG) have been proposed as they showed superior contrast 244 
efficiency owing to the reduced metabolic conversion in the case of 2DG (Nasrallah et al., 2013; 245 
Rivlin et al., 2013) or to the lack of metabolic transformation in the case of 3OMG (Rivlin et al., 246 
2014). As a consequence, such derivatives provide an improved and long-lasting CEST contrast in 247 
mice carrying xenograft tumors. On the other hand, the safety of these compounds has still to be 248 
demonstrated, since the high concentrations (> 1-1.5 g/kg b.w.) required to generate enough CEST 249 
contrast might limit their use to laboratory animals. An analogous limitation may be envisaged for 250 
the recently reported CEST agents based on salicylic acid (a metabolite of aspirin), although their 251 
very large chemical shift difference (unusual for diamagnetic CEST agents) holds promise for 252 
applications at lower magnetic fields (Lesniak et al., 2016; Yang et al., 2013). Conversely, the 253 
herein investigated excipients hold a very high safety profile, considering that they are used at high 254 
dosages to provide suitable formulations for drugs. 255 
In contrast to N-acetyl-D-glucosamine and ascorbic acid that can be metabolized within the body, 256 
sucrose (when injected i.v.) and meglumine are rapidly excreted unchanged in the urine, with no 257 
evidence for metabolism (Heeg et al., 1977). Clearly, this represents a great advantage in 258 
comparison to metabolizable probes that do not accumulated in the extracellular extravascular space 259 
of tumors. Furthermore, metabolic products cannot provide enough CEST contrast as the original 260 
molecule, with a following decrease of their observed CEST contribution. This may partly explain 261 
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the non-optimal CEST contrast in tumors upon N-acetyl-D-glucosamine administration, in 262 
comparison to the other excipients, despite the high in vitro CEST contrast efficiency. Similar 263 
findings for N-acetyl-D-glucosamine were observed by Navon group, who investigated the CEST 264 
properties of this molecule and of glucosamine as alternatives to glucose analogs (Rivlin and 265 
Navon, 2016). In our study, the observed increase in CEST contrast in tumors with N-Acetyl-D-266 
Glucosamine was lower (ΔST = 2-3%) than what previously reported (ΔST = 6-7%), albeit a 267 
similar dosage was administered. These observations may be accounted by the use of different 268 
tumor cell lines or by the lower saturation pulse power that has been applied in our experimental 269 
protocol (1.5 µT vs 2.4 µT). 270 
Meglumine showed distinct contrast enhancement capabilities between TS/A and B16 tumors. 271 
Meglumine is not internalized inside cells, therefore differences in CEST contrast enhancements are 272 
only dependent on the accumulation within the extracellular extravascular space, hence reflecting 273 
different vascularization properties. As such, this molecule can be considered an extracellular-fluid 274 
agent analogous to the clinically approved Gadolinium-based contrast agents (Morana et al., 2013) 275 
or to Iodine-containing X-ray systems (Rutten and Prokop, 2007). Thus, meglumine may be an 276 
attractive candidate to be used as MRI-CEST contrast agents for tumor imaging with remarkable 277 
contrast efficiency. 278 
 279 
5. Conclusions 280 
The herein investigated excipients show remarkable MRI-CEST properties as demonstrated by the 281 
in vivo visualization of tumors in two murine models. The extremely good safety profile of the 282 
excipients provides support to the view that these systems may be considered reliable candidates for 283 
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Figure Legends 419 
Figure 1. Chemical structures and molecular weights (g/mol) of the investigated excipients. 420 
Figure 2. CEST contrast curves for the investigated molecules (sucrose, black; N-acetyl-D-421 
glucosamine, red; 2-Pyrrolidone, grey; meglumine, green; ascorbic acid, blue) obtained at 422 
concentration of 30 mM at pH 6 (A) and pH 7.4 (B) using a saturation power level of 1.5 µT with 423 
duration of 7s at 7T and 37°C. 424 
Figure 3. CEST contrast dependence on pH measured in the range of 6-7.4 pH units at different B1 425 
levels (saturation power from 1.5 µT to 6 µT for 5s, 7T, 37°C) for sucrose (A), N-acetyl D-426 
glucosamine (B), 2-Pyrrolidone (C), meglumine (D) and ascorbic acid (E). 427 
Figure 4. Box-plots showing averaged mean ΔST increase (calculated as ST post -ST pre injection) 428 
in TS/A (grey bars) and B16 (black bar) tumor regions using B1 = 1.5µTx5s on a 7T MRI scanner. 429 
CEST contrast observed after i.v. administration of sucrose (A), N-acetyl-D-glucosamine (B), 430 
meglumine (C) and ascorbic acid (D) at a dose of 1.2 g/kg b.w. was observed at 10, 20 and 30 431 
minutes post-injection. 432 
Figure 5. Representative ΔST tumor maps overimposed on anatomical images showing CEST 433 
contrast increase for sucrose, N-acetyl-D-glucosamine, meglumine and ascorbic acid 20 min after 434 
i.v. administration using B1 = 1.5 µT x 5s in B16 (top row) and TS/A (bottom row) tumors.    435 
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Figure 6. Box-plot showing extravasation fraction calculated as percentage of pixels with ΔST 436 
higher than 2% for sucrose, N-acetyl-D-glucosamine, meglumine and ascorbic acid 20 min after i.v 437 
administration using B1= 1.5 µT x 5s for B16 (A) and TS/A (B) murine tumors. 438 
